Going China through M&A: a US growing biopharmaceutical firm
Client A US based biopharmaceutical firm
Project Realizing Positive NPV Through Horizontal Acquisition
Table of Contents Client Need Services by Amerson High ROI Delivered
Realizing Positive NPV Through Horizontal Acquisition
Client Need
Our client is a technology driven active pharmaceutical ingredients (API) developer utilizing its patented discovery methodology with proven records of success for cost saving development of several prosperous drug candidates. But with the increment of pipeline of candidates, firm is under deeper financial pressure due to lack of the further funding sources, senior management is looking for ways to solve this financial problem.
With the referral from an existing savvy client of Amerson, the firm decided to hire Amerson to help formulating its financial and global strategies and practical tactics.
Services by Amerson
With Amerson's unique skills and experiences in strategic planning, China pharmaceuticals and medical products marketing, and China customized business intelligence and financial analysis tools. Amerson is able to formulate an novel approach to help our client acquire the best suited target firm - a Chinese medical devices manufacturer in profits but without harmony between management and the shareholders, due to the lack of innovation and good future planning. Amerson is able to use a practical financial model generated from our in-depth understanding of China pharmaceuticals and medical products market to finalize our recommendation and detailed M&A processes to our client. Within six months, the final deal was made by both parties.
High ROI Delivered by Amerson
The deal gave our client a very positive NPV accompanying with much increased NWC and its global presence in China to further stretch out its planned drug discovery and pilot lab setup.
Contact Us
To discuss how we may help your organization, please call us toll-free at 1 (877) 717-8961. Outside the United States and Canada please dial 1 (614) 448-2382. > Send Us an e-mail > More Contacts